
Kingella kingae on blood agar is showing beta-hemolytic colonies after 48 hours incubation at 37°C as shown above image.
Scientific Classiofication
Kingella kingae is a species of Gram-negative that appears as pairs or chains of 4 to 8 plump (0.6 to 1 μm by 1 to 3 μm) coccobacilli, facultative anaerobic β-hemolytic bacterium showing non-motile, and non-spore-forming, exhibits negative catalase, urease, and indol tests, and, with rare exceptions, has oxidase activity and it is part of the bacterial flora of the throat in young children and is transmitted from child to child. When it causes disease, the clinical involvement is often subtle and preceded by a recent history of stomatitis or upper respiratory infection (URTI). First isolated by Elizabeth O. King in 1960 and it is the fifth member of the HACEK group of fastidious Gram-negative bacteria that cause endocarditis.
Following are predisposing conditions-
Kingella kingae is thought to begin infection by colonizing the pharynx, crossing the epithelium by using an RTX (repeat-in-toxin) toxin, superfamily is a group of cytolysins and cytotoxins, and entering the circulation and reaching deeper tissues, such as bones and joints.
Kingella causes-
Other species of Kingella– K. indologenes and K. denitrificans both are responsible for endocarditis whereas K. oralis found in dental plaque.
Specimens- It may depend on the nature of the infection and the most common samples are respiratory secretions, blood, and bone, and joint exudates.
K. kingae has typical features for identification and they are-
In the past, patients with central nervous system infections caused by Kingella kingae were treated with a penicillin drug alone or in combination with chloramphenicol, but currently, a third-generation cephalosporin i.e. cefotaxime or ceftriaxone as monotherapy or in combination with an aminoglycoside ( gentamicin or amikacin) for is preferred.
The empirical drug regimens for septic arthritis and osteomyelitis in young children generally combine the parenteral administration of a penicillinase-stable β-lactam antibiotic such as oxacillin and a broad-spectrum second-generation i.e cefuroxime or third-generation cephalosporin i.e. ceftriaxone.